secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001193125-25-252200
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra positive Phase 2 ADX-629 in alcohol-hepatitis; pipeline focuses on ADX-248/ADX-246; cash runway into H2 2027
--------------------------------------------------------------------------------

- ADX-629 Phase 2 trial in mild-to-moderate alcohol-associated hepatitis showed significant improvement in MELD score (P=0.001), triglycerides (P<0.0001), and CRP (P<0.0001).
- Pipeline focused on next-generation RASP modulators ADX-248 (metabolic inflammation, IND 2026) and ADX-246 (dry AMD, IND 2026); ADX-629 development discontinued.
- Cash runway extended into second half of 2027 due to pipeline prioritization.
- No serious adverse events reported in the ADX-629 trial; drug was well tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525252200/0001193125-25-252200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525252200/aldx-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-252200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer